Impact of acoramidis on clinical stability in transthyretin amyloid cardiomyopathy: observations from ATTRibute-CM

20261 citationsJournal Articlehybrid Open Access

Authors

Francesco Cappelli · Azienda Ospedaliero-Universitaria Careggi

Marianna Fontana · Amyloidosis Foundation

Pablo Garcia-Pavia · Hospital Universitario Puerta de Hierro Majadahonda

D P Judge · Medical University of South Carolina

Laura Obici · Policlinico San Matteo Fondazione

Ahmad Munir Masri · Oregon Health & Science University

Kai Vogtländer

Abstract

Acoramidis led to CMI from baseline in NT-proBNP concentration or 6MWD in a considerable proportion of participants with ATTR-CM. These findings suggest that the treatment paradigm of ATTR-CM may evolve from slowing disease progression to achieving improvement.

Topics & Keywords

Amyloidosis: Diagnosis, Treatment, Outcomes Parathyroid Disorders and Treatments Dermatological and Skeletal Disorders

Publication Details

Published in: European Journal of Heart Failure

DOI: 10.1093/ejhf/xuag048

Field-Weighted Citation Impact: 21.57

Command Palette

Impact of acoramidis on clinical stability in transthyretin amyloid cardiomyopathy: observations from ATTRibute-CM

Authors

Abstract

Topics & Keywords

Publication Details